Ovarian Cancer
Ovarian cancer is a malignant tumor originating in the ovary or nearby structures like the fallopian tubes or abdominal lining, which can spread to the uterus, abdomen, lymph nodes, liver, or lungs. It often begins with minimal or vague symptoms but may progress to cause bloating, pelvic pain, abdominal swelling, and other noticeable signs.
Health Outcomes
- Accelerated Recovery of Chemotherapy-Induced Myelosuppression
- Activated p53/BAX-Mediated DNA Damage Response
- Cancer Treatment Support
- Delayed Tumor Onset
- Downregulated Hippo Pathway Kinase Activity
- Enhanced Anticancer Capacity
- Enhanced Antitumor Immune Response
- Enhanced Antitumor Immunity
- Enhanced CD8+ T Cell Infiltration
- Enhanced Caspase-3 Activity
- Enhanced Cell Adhesion Capacity
- Enhanced Cytolytic Response of CD8+ T Cells
- Enhanced Glycolysis Pathway Activation
- Enhanced Natural Killer Cell Activity
- Enhanced Natural Killer Cell Tumor Killing Activity
- Enhanced Tumor-Targeted Drug Delivery
- Estrogen Receptor-Mediated Effects
- Genome Sequencing / Genome Characterization
- Improved Antitumor Response
- Improved Cell Viability
- Improved Chemotherapy Efficacy
- Improved Effectiveness in Cancer Treatment
- Improved NK-Cell Cytotoxicity
- Improved Natural Killer Cell Activation
- Improved Natural Killer Cell Activity
- Improved Natural Killer Cell Tumoricidal Activity
- Improved Objective Response Rate
- Improved Oncolytic Virotherapy Efficacy
- Improved Overall Survival
- Improved Pathological Response
- Improved Progression-free Survival
- Improved Response to Immune Checkpoint Inhibitor Therapy
- Improved Storage Viability
- Improved Survival
- Improved Survival Capacity
- Improved Survival Rate
- Improved Therapeutic Potential
- Improved Treatment Response Rate
- Improved Tumor Response
- Inactivated Other Receptor Tyrosine Kinase Activity
- Increased Anti-Tumor Activity
- Increased Antiangiogenic Activity
- Increased Anticancer Activity
- Increased Cell Death
- Increased Cell Division
- Increased Chromosomal Instability
- Increased Intratumoral Accumulation
- Increased Mitogenic Activity
- Increased Omentin Level
- Increased Reduced Glutathione Level
- Increased Survival Rate
- Increased Survival Time
- Increased Telomere Length
- Increased Tissue Invasion
- Increased mTORC1 Activation
- Inhibited Epithelial-Mesenchymal Transition
- Inhibited PI3K/AKT Pathway
- Maintained Natural Killer Cell Activity
- No Improvement in Objective Cancer Treatment Response
- No Serious Treatment-Related Adverse Events
- Overall Treatment Success
- Reduced Apoptosis Due to Carcinogens
- Reduced Cancer Activity
- Reduced Cancer Progression
- Reduced Cancer Risk
- Reduced Cancer-Specific Mortality
- Reduced Caspase-3 Activity
- Reduced Cell Adhesion
- Reduced Chemotherapy Side Effects
- Reduced DNA Damage
- Reduced Epithelial Cell Apoptosis
- Reduced Epithelial-Mesenchymal Transition
- Reduced Expression of STAT3-Dependent Tumor-Associated Genes
- Reduced Genotoxicity
- Reduced Pulmonary Metastasis
- Reduced Risk of Cancer
- Reduced Tumor Formation
- Reduced Tumor Grade
- Reduced Tumor Growth
- Reduced Tumor Growth Rate
- Reduced Tumor Incidence
- Reduced Tumor Multiplicity
- Reduced Tumor Risk
- Reduced Tumor Stage
- Reduced Tumor Volume
- Regulated miR-130a-5p Levels
- Shifted Tumor-Associated Macrophages Toward Pro-Inflammatory M1 Polarization
- Suppressed Tumor Growth
- Targeted Tumor Reduction